MONOCLONAL ANTIBODIES A NEW ERA IN DISEASE MANAGEMENT

Abstract

Monoclonal antibodies (mAbs) offer targeted therapy for various diseases, providing high efficacy with fewer side effects than conventional treatments. Introduction: mAbs are widely used in cancer, autoimmune disorders, and infectious diseases, revolutionizing personalized medicine. A review of approved mAbs, clinical trials, and emerging innovations was conducted to evaluate their impact. mAbs like Rituximab, Adalimumab, and Casirivimab have shown significant success, but challenges like high costs and immune resistance persist With advancements in bispecific antibodies and nanobody therapies, mAbs continue to shape the future of targeted therapy and precision medicine.